Source link : https://newshealth.biz/health-news/pam-inhibitor-approved-for-hr-positive-breast-cancer/
The FDA approved the kinase inhibitor gedatolisib (Revtorpyk) for treating hormone receptor (HR)-positive/HER2-negative breast cancer in patients whose disease has progressed on endocrine therapy in the metastatic setting. Approval of the PI3K/AKT/mTOR (PAM) inhibitor stipulates use in combination with fulvestrant — with or without the CDK4/6 inhibitor palbociclib (Ibrance) — in adults without PIK3CA mutations. […]
The post PAM Inhibitor Approved for HR-Positive Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-07-14 21:40:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8